Europe Colorectal Cancer Screening Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 4.20 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Colorectal Cancer Screening Market Analysis
The Europe colorectal cancer screening market is expected to grow at a CAGR of 4.2% during the forecast period.
- The COVID-19 pandemic affected healthcare systems in Europe. It also resulted in the interruption of usual care in many healthcare facilities. The pandemic posed several difficulties for the oncology community, particularly in diagnosing and treating cancer patients while guaranteeing both patient and professional immunity to the virus. A reduction in hospital visits, the discontinuation of the screening programs, and challenges with managing and operating cancer registries were major factors that were affected during the pandemic.
- However, governments across countries in Europe took initiatives to overcome the losses incurred by the pandemic. According to an article published in April 2021 in World Journal of Gastrointestinal Oncology (WJGO), to overcome COVID-19-related disruption, strategies were applied, which included utilizing stool-based cancer tests, developing screening protocols based on individual risk factors, expanding telehealth, and increasing open access colonoscopies.
- As per the source mentioned above, in Europe, a positive fecal immunochemical test (FIT) was recommended, followed up by a colonoscopy. Likewise, strategies and initiatives were adopted across European countries to manage colorectal cancer screening. Thus, these strategies and initiatives during and post-pandemic period in Europe impacted the market significantly. Hence, the market for colorectal screening is witnessing growth over the post-pandemic phase in Europe.
- The advent of efficacious genetic tests, the growing prevalence of colorectal cancer, and increasing cancer prevention initiatives are the primary factors that contribute to market growth.
- Colorectal cancer (CRC) comprises cancer of the colon and rectum. This is one of the most diagnosed forms of cancer and is responsible for severe mortality incidences. According to a press release by DiCE in June 2022, CRC is the 3rd most diagnosed cancer in men and the 2nd in women in Europe, with considerable variability among the 27 countries of the European Union. This shows that CRC creates a high burden on healthcare in Europe. Thus, the burden of CRC establishes a need for cancer screening for better diagnosis and treatment. This is expected to fuel the market growth over the forecast period.
- Additionally to a press release by the EC in March 2022, most European countries conduct screening for colorectal cancer. However, these existing services must be improved and updated to detect more colorectal cancer. This further creates demand for the availability of advanced and innovative devices, new cancer screening strategies, and initiatives, fuelling the market growth.
- Moreover, major players focus more on product development and innovation for CRC screening in the region. For instance, in November 2021, Fujifilm launched ColoAssist PRO, a real-time endoscope visualization system designed to assist endoscopists in performing colonoscopies. ColoAssist PRO is the latest system of Fujifilm's ELUXEO Ultra family of technologies. These innovations in technology and products are anticipated to fuel market growth over the forecast period.
- Therefore, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, the high costs associated with screenings are expected to restrain the market growth.
Europe Colorectal Cancer Screening Market Trends
This section covers the major market trends shaping the Europe Colorectal Cancer Screening Market according to our research experts:
Colonoscopy Segment is Anticipated to Witness Significant Growth Over the Forecast Period
- Compared to other market segments, the colonoscopy segment is expected to witness growth during the forecast period. The colonoscopy procedure is painless and helps remove abnormal tissue before it becomes cancerous. Due to such benefits, colonoscopy is considered the gold standard for colorectal cancer screening. Thus, the segment is expected to witness growth.
- Colonoscopy allows for the detection of early neoplasia and the removal of precancerous lesions, which has been demonstrated to lower the incidence and mortality of CRC significantly. The increase in CRC cases in Europe requires better screening procedures for disease detection and treatment. Thus, increasing awareness regarding colonoscopy and its benefits well known to the public is essential.
- In this context, ECQI Group aims to raise awareness for improved European colonoscopy standards. According to an article published in MDPI in February 2022, when a survey was conducted to evaluate the achievement of the European Society of Gastrointestinal Endoscopy (ESGE) mean withdrawal time (WT) target, most of the samples met the minimum standards set by the ECQI during the colonoscopy procedures. This argues for a better understanding of colonoscopy among the users regarding the same. Thus, this shows that the population of Europe is aware of the need for improved colonoscopy standards across Europe. This awareness is increasing the number of colonoscopy procedures for CRC screening in Europe. Hence, it is expected to fuel the segment's growth over the forecast period.
- Furthermore, having a fecal occult blood test often leads to additional testing. If the fecal occult blood test result is positive, doctors recommend a test such as a colonoscopy to examine the inside of the colon in general. As per an article published in the journal of Gastrointestinal Disorders in June 2022, CRC screening can help reduce the incidence and mortality of the disease. Hence, patients with a positive fecal occult blood test are typically advised to have a colonoscopy for additional testing. Thus, the region's demand for colonoscopies is increasing due to the high burden of CRC in Europe. Thereby, driving the segment growth.
- Hence, the studied segment is expected to witness growth during the forecast period due to the factors mentioned above.
United Kingdom is Anticipated to Contribute Significantly to the Market Growth Over the Forecast Period
- The United Kingdom is expected to significantly contribute to the overall market growth during the forecast period. The growing prevalence of CRC and the increasing number of initiatives for CRC screening are the major factors contributing to the country's market growth.
- Bowel cancer is also known as colorectal cancer, and it affects the large bowel, which is made up of the colon and rectum. With the increasing burden of CRC in the United Kingdom, the demand for the availability of cancer screening in the country is also increasing.
- The 2022 update by Bower Cancer UK shows that bowel cancer is the 4th most common cancer, and approximately 43,000 people are diagnosed with bowel cancer every year in the United Kingdom. This creates a huge healthcare burden in the country and creates demand for screening for early detection of the disease. This is further expected to fuel the market growth in the United Kingdom.
- Furthermore, the United Kingdom's government is more focused on providing better diagnosis and treatment options to the target population and controlling the disease burden. Thus, together with the NHS foundation, the country's government offers bowel cancer screening for people aged 60 to 74 every two years.
- Furthermore, according to the data updated by the government of the United Kingdom in its press release in July 2022, NHS is gradually extending this age range, and people aged 56 or more are now being invited as part of this CRC screening process. In addition, the data updated by the Nuffield Trust in June 2022 stated that there are national screening programs for breast, cervical, and bowel cancer in the United Kingdom, and these services save nearly 9,000 lives every year. Thus, such initiatives in the country propel colorectal cancer screening and drive overall market growth.
- Thus, the market is expected to witness a high growth rate over the forecast period due to the aforementioned factors in the United Kingdom.
Europe Colorectal Cancer Screening Industry Overview
The Europe colorectal cancer screening market is competitive and consists of several significant players across the region. The key players are developing novel products to compete with the existing products, while others are acquiring and partnering with the other companies trending in the market to expand their presence. Some market players in the studied market are Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Novigenix SA, Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation, Olympus Corporation, Stryker, and FUJIFILM Corporation.
Europe Colorectal Cancer Screening Market Leaders
-
Abbott Laboratories
-
Epigenomics Inc.
-
Exact Sciences Corporation
-
F. Hoffmann-La Roche AG
-
Novigenix SA
*Disclaimer: Major Players sorted in no particular order
Europe Colorectal Cancer Screening Market News
- September 2022: The International Agency for Research on Cancer (IARC) and its partners launched a new research project funded by the European Union (EU) to strengthen cancer screening data collection across Europe, especially for breast cancer, cervical cancer, and colorectal cancer. The CanScreen-ECIS project coordinated by IARC aims to update the existing European Cancer Information System (ECIS) and improve the quality and coverage of cancer screening programs in Europe.
- April 2022: SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, received an additional clearance for its G-EYE Colonoscope from the Food and Drug Administration (FDA) based on Olympus' 510(k) cleared PCF colonoscope series.
Europe Colorectal Cancer Screening Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Advent of Efficacious Genetic Tests
- 4.2.2 Growing Prevalence of Colorectal Cancer
- 4.2.3 Increasing Cancer Prevention Initiatives
-
4.3 Market Restraints
- 4.3.1 High Cost of the Screeing Tests
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 Screening Tests
- 5.1.1 Stool-based Tests
- 5.1.1.1 Fecal Immunochemical Test (FIT)
- 5.1.1.2 Guaiac-based Fecal Occult Blood Test (gFOBT)
- 5.1.1.3 Stool DNA Test
- 5.1.2 Colonoscopy
- 5.1.3 CT Colonography (Virtual Colonoscopy)
- 5.1.4 Flexible Sigmoidoscopy
- 5.1.5 Other Tests
-
5.2 By End User
- 5.2.1 Hospitals
- 5.2.2 Diagnostic Centers
-
5.3 Geography
- 5.3.1 Germany
- 5.3.2 United Kingdom
- 5.3.3 France
- 5.3.4 Italy
- 5.3.5 Spain
- 5.3.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Epigenomics Inc.
- 6.1.3 Exact Sciences Corporation
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 Novigenix SA
- 6.1.6 Quidel Corporation
- 6.1.7 Siemens Healthineers AG
- 6.1.8 Sysmex Corporation
- 6.1.9 Olympus Corporation
- 6.1.10 Stryker
- 6.1.11 FUJIFILM Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Colorectal Cancer Screening Industry Segmentation
As per the scope of the report, colorectal cancer (CRC) is known as bowel and colon cancer. CRC screening tests use kits and various medical devices for diagnosing cancer.
The Europe colorectal cancer screening market is segmented by screening tests (stool-based tests, colonoscopy, CT colonography (virtual colonoscopy), flexible sigmoidoscopy and other tests), and end-user (hospitals and diagnostic centers), and geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe).
The report offers the value (in USD million) for the above segments.
| Screening Tests | Stool-based Tests | Fecal Immunochemical Test (FIT) |
| Guaiac-based Fecal Occult Blood Test (gFOBT) | ||
| Stool DNA Test | ||
| Screening Tests | Colonoscopy | |
| CT Colonography (Virtual Colonoscopy) | ||
| Flexible Sigmoidoscopy | ||
| Other Tests | ||
| By End User | Hospitals | |
| Diagnostic Centers | ||
| Geography | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe |
Europe Colorectal Cancer Screening Market Research FAQs
What is the current Europe Colorectal Cancer Screening Market size?
The Europe Colorectal Cancer Screening Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)
Who are the key players in Europe Colorectal Cancer Screening Market?
Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG and Novigenix SA are the major companies operating in the Europe Colorectal Cancer Screening Market.
What years does this Europe Colorectal Cancer Screening Market cover?
The report covers the Europe Colorectal Cancer Screening Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Colorectal Cancer Screening Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Colonoscopy Industry Report
Statistics for the 2023 Europe Colonoscopy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Colonoscopy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
